Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...
Taking on a side hustle could benefit you financially. But read on to see why it may not work out as well as planned.
Businesses may rush to front load imports into the US to avoid higher tariffs after Trump takes office.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback